Abstract
Objective Chagas disease (CD) continues to be a major public health burden in Latina America, where co-infection with SARS-CoV-2 can occur. However, information on the interplay between COVID-19 and Chagas disease is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients.
Methods Patients with COVID-19 diagnosis were selected from the Brazilian COVID-19 Registry, a prospective multicenter cohort, from March to September, 2020. CD diagnosis was based on hospital record at the time of admission. Study data were collected by trained hospital staff using Research Electronic Data Capture (REDCap) tools. Genetic matching for sex, age, hypertension, DM and hospital was performed in a 4:1 ratio.
Results Of the 7,018 patients who had confirmed infection with SARS-CoV-2 in the registry, 31 patients with CD and 124 matched controls were included. Overall, the median age was 72 (64.-80) years-old and 44.5% were male. At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p<0.05 for both). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). Seventy-two (46.5%) patients required admission to the intensive care unit. In-hospital management, outcomes and complications were similar between the groups.
Conclusions In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.
What is already known about this subject?
Preexisting cardiovascular disease enhances vulnerability to COVID-19.
Co-infection with SARS-CoV-2 and T.cruzi can occur in patients living in areas in which both infections are epidemic.
What does this study add?
Despite a higher frequency of chronic heart failure and atrial fibrillation, our findings do not suggest that co-infection with T.cruzi and SARS-CoV-2 worsens in-hospital outcomes.
Chagas disease patients were observed to have lower C-reactive protein (CRP) levels.
How might this impact on clinical practice?
Given the current circulation of SARS-CoV-2 at high levels and millions of T cruzi-infected individuals living in Brazil, the risk for co-infections substantially increases.
Further studies are needed to investigate why CRP levels were lower in CD patients. We hypothesized that CD patients might have a lower risk of unregulated inflammatory response to COVID-19, as they already have an active chronic inflammatory and immune response response triggered by T.cruzi infection.
- Chagas disease
- COVID-19
- prognosis
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by Minas Gerais State Agency for Research and Development (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, FAPEMIG) [grant number APQ-00208-20], National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliacoo de Tecnologias em Saude, IATS)/ National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq) [grant number 465518/2014-1], and CAPES Foundation (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) [grant number 88887.507149/2020-00].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics The study was approved by the National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived owing to the pandemic situation and the use of deidentified data, based on medical chart review only.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(Romero IM - israel.molina{at}fiocruz.br)
(Marcolino MS - milenamarc{at}ufmg.br)
(Pires MC – magda{at}est.ufmg.br)
(Ramos LEF - luckermos19{at}gmail.com)
(Silva RT - rafaelsilva{at}posteo.net)
(Guimarães Júnior MH - miltonhenriques{at}yahoo.com.br)
(Oliveira IJR - isaias.ramos{at}gmail.com)
(Carvalho RLR - rafaelsjdr{at}hotmail.com)
(Nunes AGS - alinegsn89{at}yahoo.com.br)
(Barros ALRM - barrosanalara{at}gmail.com)
(Scotton ALBA - analuiza.bahia{at}yahoo.com.br)
(Madureira AAC - angelicaacmadureira{at}gmail.com)
(Farace BL - barbarafarace{at}gmail.com)
(Carvalho CA - carvalho.cintiaa{at}gmail.com)
(Rodrigues DA - fe.athayde{at}gmail.com)
(Anschau F - afernando{at}ghc.com.br)
(Botoni FA - fbotoni{at}medicina.ufmg.br)
(Nascimento GF - guilhermefagundesn{at}hotmail.com)
(Duani H - hduani{at}yahoo.com.br)
(Guimarães HC - hcerqueirag{at}gmail.com)
(Alvarenga JC - joice-alvarenga{at}hotmail.com)
(Moreira LB - lbmoreira{at}hcpa.edu.br)
(Zandoná LB - liegezandona{at}hotmail.com)
(Almeida LF - luana.fonseca.almeida{at}gmail.com)
(Oliveira LM - luanalmo19.09{at}gmail.com)
(Kopittke L - kluciane{at}ghc.com.br)
(Castro LC - pharmlucamsc{at}gmail.com)
(Santos LEA, luisa_elem{at}hotmail.com)
(Cabral MAS - madersonalvares{at}hotmail.com)
(Ferreira MAP - mpiferreira{at}hcpa.edu.br)
(Sampaio NCS - natsamster{at}gmail.com)
(Oliveira NR - neimyramos{at}gmail.com)
(Francisco SC - saionaracf{at}gmail.com)
(Lopes SJTS - sofiajarjour{at}gmail.com)
(Fereguetti TO - tatianifereguetti{at}gmail.com)
(Santos VB - veridbaldon{at}hotmail.com)
(Carvalho VEB - perillo.victor{at}gmail.com)
(Ramires YC - yuri.ramires{at}gmail.com)
(Ribeiro ALP - tom{at}hc.ufmg.br)
(Moscoso FAB - cardio.britom{at}gmail.com)
(Moura R - professor{at}cursointensivocardio.com.br)
(Polanczyk CA - carisi.anne{at}gmail.com)
(Nunes MCP - mcarmo{at}waymail.com.br)
Data Availability
Data are available upon reasonable request.
